While this leads to resistance to CD8+ T cell-dependent therapies like checkpoint blockade, studies reveal that in B2M-inactivated tumors, anti-tumor immunity can be alternatively mediated by activated CD4+ T cells and NK cells, uncovering a compensatory immune response pathway (Torrejon et al., 2023). Here, CD4 is linked to neoplasm.